DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Rare. ~1-2 cases per 1000 patient-years. Risk factors: prior pancreatitis, heavy alcohol use, gallstones. Severe abdominal pain warrants immediate discontinuation.
GLP-1 medications carry a labeled risk of acute pancreatitis. Real-world incidence is low: 1-2 cases per 1000 patient-years in clinical trials. Risk factors: history of pancreatitis (contraindicated), heavy alcohol use, gallstone disease, severe hypertriglyceridemia. Symptoms: severe abdominal pain radiating к back, often с nausea and vomiting. NOT typical GI side effects — this is sharper, more localized, persistent. Action: discontinue Wegovy immediately, seek ER care, lipase + amylase + abdominal CT. If confirmed: lifetime contraindication к GLP-1s. Recovery: most cases resolve с supportive care over 5-10 days.
Editorial answer reviewed by a board-certified clinician. Not medical advice. Coordinate treatment decisions with your prescriber.